You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR SUMATRIPTAN AND NAPROXEN SODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SUMATRIPTAN AND NAPROXEN SODIUM

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00240617 ↗ Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks Completed GlaxoSmithKline Phase 3 2005-10-01 The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
NCT00240630 ↗ Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks Completed GlaxoSmithKline Phase 3 2005-10-01 The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
NCT00329355 ↗ Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA) Completed GlaxoSmithKline Phase 3 2006-05-01 This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine.
NCT00329459 ↗ Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea Completed GlaxoSmithKline Phase 3 2006-05-01 This study was designed to determine efficacy of TREXIMA compared to placebo for the treatment of a menstrual migraine.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SUMATRIPTAN AND NAPROXEN SODIUM

Condition Name

Condition Name for SUMATRIPTAN AND NAPROXEN SODIUM
Intervention Trials
Migraine Disorders 15
Migraine 6
Migraine Headaches 2
Migraine With or Without Aura 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SUMATRIPTAN AND NAPROXEN SODIUM
Intervention Trials
Migraine Disorders 25
Headache 2
Premenstrual Syndrome 2
Migraine without Aura 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SUMATRIPTAN AND NAPROXEN SODIUM

Trials by Country

Trials by Country for SUMATRIPTAN AND NAPROXEN SODIUM
Location Trials
United States 289
China 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SUMATRIPTAN AND NAPROXEN SODIUM
Location Trials
Tennessee 13
Texas 12
Ohio 12
Florida 12
North Carolina 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SUMATRIPTAN AND NAPROXEN SODIUM

Clinical Trial Phase

Clinical Trial Phase for SUMATRIPTAN AND NAPROXEN SODIUM
Clinical Trial Phase Trials
Phase 4 5
Phase 3 14
Phase 2/Phase 3 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SUMATRIPTAN AND NAPROXEN SODIUM
Clinical Trial Phase Trials
Completed 23
Unknown status 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SUMATRIPTAN AND NAPROXEN SODIUM

Sponsor Name

Sponsor Name for SUMATRIPTAN AND NAPROXEN SODIUM
Sponsor Trials
GlaxoSmithKline 19
POZEN 2
West China Hospital 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SUMATRIPTAN AND NAPROXEN SODIUM
Sponsor Trials
Industry 23
Other 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.